New therapeutic drugs in the management of chronic obstructive pulmonary disease

Stephen Israel Rennard

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease remains a major health problem for which new and improved treatments are desperately needed. Recent trials strongly suggest that treatments are improving. Longer-acting bronchodilators will be more convenient and may have additional advantages. Combinations of bronchodilators may offer additive effects and, possibly, synergies. Inhaled glucocorticoids, although unable to alter the loss of forced expiratory volume in 1 second when used alone, may reduce exacerbation frequency and health status deterioration and improve mortality. These clinically meaningful goals represent end points not previously targeted in chronic obstructive pulmonary disease drug development. Moreover, inhaled glucocorticoids may offer benefits in combination with long-acting β-agonists. Finally, new classes of agents such as the phosphodiesterase inhibitors are on the horizon. The prospect for better treatment of chronic obstructive pulmonary disease looks brighter than ever. Caution is required, however. Much of the excitement has been generated by small studies, presented only in abstract form, and as yet unpublished work. Therapeutic recommendations will require publication of appropriately designed and adequately powered clinical trials.

Original languageEnglish (US)
Pages (from-to)106-111
Number of pages6
JournalCurrent Opinion in Pulmonary Medicine
Volume8
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Chronic Obstructive Pulmonary Disease
Bronchodilator Agents
Glucocorticoids
Pharmaceutical Preparations
Phosphodiesterase Inhibitors
Forced Expiratory Volume
Health Status
Publications
Therapeutics
Clinical Trials
Mortality
Health

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

New therapeutic drugs in the management of chronic obstructive pulmonary disease. / Rennard, Stephen Israel.

In: Current Opinion in Pulmonary Medicine, Vol. 8, No. 2, 01.01.2002, p. 106-111.

Research output: Contribution to journalReview article

@article{9f72776045884bb5be36067586ad0166,
title = "New therapeutic drugs in the management of chronic obstructive pulmonary disease",
abstract = "Chronic obstructive pulmonary disease remains a major health problem for which new and improved treatments are desperately needed. Recent trials strongly suggest that treatments are improving. Longer-acting bronchodilators will be more convenient and may have additional advantages. Combinations of bronchodilators may offer additive effects and, possibly, synergies. Inhaled glucocorticoids, although unable to alter the loss of forced expiratory volume in 1 second when used alone, may reduce exacerbation frequency and health status deterioration and improve mortality. These clinically meaningful goals represent end points not previously targeted in chronic obstructive pulmonary disease drug development. Moreover, inhaled glucocorticoids may offer benefits in combination with long-acting β-agonists. Finally, new classes of agents such as the phosphodiesterase inhibitors are on the horizon. The prospect for better treatment of chronic obstructive pulmonary disease looks brighter than ever. Caution is required, however. Much of the excitement has been generated by small studies, presented only in abstract form, and as yet unpublished work. Therapeutic recommendations will require publication of appropriately designed and adequately powered clinical trials.",
author = "Rennard, {Stephen Israel}",
year = "2002",
month = "1",
day = "1",
doi = "10.1097/00063198-200203000-00005",
language = "English (US)",
volume = "8",
pages = "106--111",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - New therapeutic drugs in the management of chronic obstructive pulmonary disease

AU - Rennard, Stephen Israel

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Chronic obstructive pulmonary disease remains a major health problem for which new and improved treatments are desperately needed. Recent trials strongly suggest that treatments are improving. Longer-acting bronchodilators will be more convenient and may have additional advantages. Combinations of bronchodilators may offer additive effects and, possibly, synergies. Inhaled glucocorticoids, although unable to alter the loss of forced expiratory volume in 1 second when used alone, may reduce exacerbation frequency and health status deterioration and improve mortality. These clinically meaningful goals represent end points not previously targeted in chronic obstructive pulmonary disease drug development. Moreover, inhaled glucocorticoids may offer benefits in combination with long-acting β-agonists. Finally, new classes of agents such as the phosphodiesterase inhibitors are on the horizon. The prospect for better treatment of chronic obstructive pulmonary disease looks brighter than ever. Caution is required, however. Much of the excitement has been generated by small studies, presented only in abstract form, and as yet unpublished work. Therapeutic recommendations will require publication of appropriately designed and adequately powered clinical trials.

AB - Chronic obstructive pulmonary disease remains a major health problem for which new and improved treatments are desperately needed. Recent trials strongly suggest that treatments are improving. Longer-acting bronchodilators will be more convenient and may have additional advantages. Combinations of bronchodilators may offer additive effects and, possibly, synergies. Inhaled glucocorticoids, although unable to alter the loss of forced expiratory volume in 1 second when used alone, may reduce exacerbation frequency and health status deterioration and improve mortality. These clinically meaningful goals represent end points not previously targeted in chronic obstructive pulmonary disease drug development. Moreover, inhaled glucocorticoids may offer benefits in combination with long-acting β-agonists. Finally, new classes of agents such as the phosphodiesterase inhibitors are on the horizon. The prospect for better treatment of chronic obstructive pulmonary disease looks brighter than ever. Caution is required, however. Much of the excitement has been generated by small studies, presented only in abstract form, and as yet unpublished work. Therapeutic recommendations will require publication of appropriately designed and adequately powered clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0036168805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036168805&partnerID=8YFLogxK

U2 - 10.1097/00063198-200203000-00005

DO - 10.1097/00063198-200203000-00005

M3 - Review article

VL - 8

SP - 106

EP - 111

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 2

ER -